The FDA declined to approve SYD-101, a low-dose atropine formulation that would have been the first pharmaceutical treatment ...

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...

The FDA has approved once-daily oral Lynkuet for the treatment of moderate to severe hot flashes caused by menopause, ...

The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia with a ...

Preliminary results presented here showed use of a custom-tailored AI platform may be a feasible option to address ...

Academic medicine can be a rewarding path filled with opportunities for personal and professional growth, from teaching ...

Topcon Healthcare launched IDHea Inc., a company focused on driving clinical research and oculomics to advance eye care, ...

Women who experience menopause at an earlier age and have a reduction in cardiac function are at increased risk for adverse ...

Adults with mild to severe obstructive sleep apnea achieved lower disease severity with AD109, an oral combination drug, at ...

Progesterone and dehydroepiandrosterone, but not estrogen and testosterone, may influence psoriasis pathogenesis, severity ...

Among individuals with MS, the risk of serious infection was higher and the time to the first serious infection was shorter ...

I have been a psychiatrist for 20 years. I built Kaiser Permanente’s largest behavioral health integration program at its ...